132 related articles for article (PubMed ID: 10805158)
1. Herpes simplex virus type 2 growth and latency reactivation by cocultivation are inhibited with antisense oligonucleotides complementary to the translation initiation site of the large subunit of ribonucleotide reductase (RR1).
Aurelian L; Smith CC
Antisense Nucleic Acid Drug Dev; 2000 Apr; 10(2):77-85. PubMed ID: 10805158
[TBL] [Abstract][Full Text] [Related]
2. The PK domain of the large subunit of herpes simplex virus type 2 ribonucleotide reductase (ICP10) is required for immediate-early gene expression and virus growth.
Smith CC; Peng T; Kulka M; Aurelian L
J Virol; 1998 Nov; 72(11):9131-41. PubMed ID: 9765459
[TBL] [Abstract][Full Text] [Related]
3. Ras-GAP binding and phosphorylation by herpes simplex virus type 2 RR1 PK (ICP10) and activation of the Ras/MEK/MAPK mitogenic pathway are required for timely onset of virus growth.
Smith CC; Nelson J; Aurelian L; Gober M; Goswami BB
J Virol; 2000 Nov; 74(22):10417-29. PubMed ID: 11044086
[TBL] [Abstract][Full Text] [Related]
4. A growth and latency compromised herpes simplex virus type 2 mutant (ICP10DeltaPK) has prophylactic and therapeutic protective activity in guinea pigs.
Wachsman M; Kulka M; Smith CC; Aurelian L
Vaccine; 2001 Feb; 19(15-16):1879-90. PubMed ID: 11228357
[TBL] [Abstract][Full Text] [Related]
5. The novel protein kinase of the RR1 subunit of herpes simplex virus has autophosphorylation and transphosphorylation activity that differs in its ATP requirements for HSV-1 and HSV-2.
Peng T; Hunter JR; Nelson JW
Virology; 1996 Feb; 216(1):184-96. PubMed ID: 8614985
[TBL] [Abstract][Full Text] [Related]
6. Vaccine potential of a herpes simplex virus type 2 mutant deleted in the PK domain of the large subunit of ribonucleotide reductase (ICP10).
Aurelian L; Kokuba H; Smith CC
Vaccine; 1999 Apr; 17(15-16):1951-63. PubMed ID: 10217594
[TBL] [Abstract][Full Text] [Related]
7. Herpes simplex virus type 2: unique biological properties include neoplastic potential mediated by the PK domain of the large subunit of ribonucleotide reductase.
Aurelian L
Front Biosci; 1998 Feb; 3():d237-49. PubMed ID: 9459654
[TBL] [Abstract][Full Text] [Related]
8. The herpes simplex virus type 2 R1 protein kinase (ICP10 PK) blocks apoptosis in hippocampal neurons, involving activation of the MEK/MAPK survival pathway.
Perkins D; Pereira EF; Gober M; Yarowsky PJ; Aurelian L
J Virol; 2002 Feb; 76(3):1435-49. PubMed ID: 11773417
[TBL] [Abstract][Full Text] [Related]
9. The 140-kDa RR1 protein from both HSV-1 and HSV-2 contains an intrinsic protein kinase activity capable of autophosphorylation but it is transphosphorylation defective.
Ali MA
Virology; 1995 Mar; 207(2):409-16. PubMed ID: 7886945
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of herpes simplex virus reactivation by dipyridamole in a mouse model.
Hay KA; Gaydos A; Tenser RB
J Med Virol; 1996 Oct; 50(2):198-203. PubMed ID: 8915888
[TBL] [Abstract][Full Text] [Related]
11. Synergistic antiviral activities of oligonucleoside methylphosphonates complementary to herpes simplex virus type 1 immediate-early mRNAs 4, 5, and 1.
Kulka M; Smith CC; Levis J; Fishelevich R; Hunter JC; Cushman CD; Miller PS; Ts'o PO; Aurelian L
Antimicrob Agents Chemother; 1994 Apr; 38(4):675-80. PubMed ID: 8031030
[TBL] [Abstract][Full Text] [Related]
12. Development of HSV-specific CD4+ Th1 responses and CD8+ cytotoxic T lymphocytes with antiviral activity by vaccination with the HSV-2 mutant ICP10DeltaPK.
Gyotoku T; Ono F; Aurelian L
Vaccine; 2002 Jun; 20(21-22):2796-807. PubMed ID: 12034107
[TBL] [Abstract][Full Text] [Related]
13. Leucine repeats in the large subunit of herpes simplex virus type 2 ribonucleotide reductase (RR; ICP10) are involved in RR activity and subunit complex formation.
Chung TD; Luo JH; Wymer JP; Smith CC; Aurelian L
J Gen Virol; 1991 May; 72 ( Pt 5)():1139-44. PubMed ID: 1851814
[TBL] [Abstract][Full Text] [Related]
14. Reduction of herpes simplex virus type-2 replication in cell cultures and in rodent models with peptide-conjugated morpholino oligomers.
Eide K; Moerdyk-Schauwecker M; Stein DA; Bildfell R; Koelle DM; Jin L
Antivir Ther; 2010; 15(8):1141-9. PubMed ID: 21149921
[TBL] [Abstract][Full Text] [Related]
15. Antiviral effect of oligo(nucleoside methylphosphonates) complementary to the herpes simplex virus type 1 immediate early mRNAs 4 and 5.
Kulka M; Wachsman M; Miura S; Fishelevich R; Miller PS; Ts'o PO; Aurelian L
Antiviral Res; 1993 Feb; 20(2):115-30. PubMed ID: 8384823
[TBL] [Abstract][Full Text] [Related]
16. Herpes simplex virus-mediated activation of human immunodeficiency virus is inhibited by oligonucleoside methylphosphonates that target immediate-early mRNAs 1 and 3.
Feng CP; Kulka M; Smith C; Aurelian L
Antisense Nucleic Acid Drug Dev; 1996; 6(1):25-35. PubMed ID: 8783793
[TBL] [Abstract][Full Text] [Related]
17. Herpes simplex virus-encoded ribonucleotide reductase: evidence for the dissociation/reassociation of the holoenzyme.
Darling AJ; McKay EM; Ingemarson R; Booth B
Virus Genes; 1990 Apr; 3(4):367-72. PubMed ID: 2161585
[TBL] [Abstract][Full Text] [Related]
18. AP-1 cis-response elements are involved in basal expression and Vmw110 transactivation of the large subunit of herpes simplex virus type 2 ribonucleotide reductase (ICP10).
Zhu J; Aurelian L
Virology; 1997 May; 231(2):301-12. PubMed ID: 9168892
[TBL] [Abstract][Full Text] [Related]
19. The herpes simplex virus type 2 R1 protein kinase (ICP10 PK) functions as a dominant regulator of apoptosis in hippocampal neurons involving activation of the ERK survival pathway and upregulation of the antiapoptotic protein Bag-1.
Perkins D; Pereira EF; Aurelian L
J Virol; 2003 Jan; 77(2):1292-305. PubMed ID: 12502846
[TBL] [Abstract][Full Text] [Related]
20. Modified adenovirus penton base protein (UTARVE) as a non-replicating vector for delivery of antisense oligonucleotides with antiviral and/or antineoplastic activity.
Smith CC; Kulka M; Aurelian L
Int J Oncol; 2000 Oct; 17(4):841-50. PubMed ID: 10995900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
